Diverticular Disease and Rifaximin: An Evidence-Based Review
There have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications. Rifaximin, a non-absorbable antibiotic, is a common therapeutic choice for symptomatic diverticular disease in various countrie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/12/3/443 |
| _version_ | 1797613852320333824 |
|---|---|
| author | Anna Piccin Marco Gulotta Stefano di Bella Paola Martingano Lory Saveria Crocè Mauro Giuffrè |
| author_facet | Anna Piccin Marco Gulotta Stefano di Bella Paola Martingano Lory Saveria Crocè Mauro Giuffrè |
| author_sort | Anna Piccin |
| collection | DOAJ |
| description | There have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications. Rifaximin, a non-absorbable antibiotic, is a common therapeutic choice for symptomatic diverticular disease in various countries, including Italy. Because of its low systemic absorption and high concentration in stools, it is an excellent medicine for targeting the gastrointestinal tract, where it has a beneficial effect in addition to its antibacterial properties. Current evidence shows that cyclical rifaximin usage in conjunction with a high-fiber diet is safe and effective for treating symptomatic uncomplicated diverticular disease, while the cost-effectiveness of long-term treatment is unknown. The use of rifaximin to prevent recurrent diverticulitis is promising, but further studies are needed to confirm its therapeutic benefit. Unfortunately, there is no available evidence on the efficacy of rifaximin treatment for acute uncomplicated diverticulitis. |
| first_indexed | 2024-03-11T07:01:27Z |
| format | Article |
| id | doaj.art-665c7c6aa34848f9b199f770801380a8 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-11T07:01:27Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-665c7c6aa34848f9b199f770801380a82023-11-17T09:13:02ZengMDPI AGAntibiotics2079-63822023-02-0112344310.3390/antibiotics12030443Diverticular Disease and Rifaximin: An Evidence-Based ReviewAnna Piccin0Marco Gulotta1Stefano di Bella2Paola Martingano3Lory Saveria Crocè4Mauro Giuffrè5Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyDepartment of Radiology, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), 34128 Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyThere have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications. Rifaximin, a non-absorbable antibiotic, is a common therapeutic choice for symptomatic diverticular disease in various countries, including Italy. Because of its low systemic absorption and high concentration in stools, it is an excellent medicine for targeting the gastrointestinal tract, where it has a beneficial effect in addition to its antibacterial properties. Current evidence shows that cyclical rifaximin usage in conjunction with a high-fiber diet is safe and effective for treating symptomatic uncomplicated diverticular disease, while the cost-effectiveness of long-term treatment is unknown. The use of rifaximin to prevent recurrent diverticulitis is promising, but further studies are needed to confirm its therapeutic benefit. Unfortunately, there is no available evidence on the efficacy of rifaximin treatment for acute uncomplicated diverticulitis.https://www.mdpi.com/2079-6382/12/3/443diverticulosisdiverticular diseaseacute diverticulitisrifaximinfiber supplementationmicrobiota |
| spellingShingle | Anna Piccin Marco Gulotta Stefano di Bella Paola Martingano Lory Saveria Crocè Mauro Giuffrè Diverticular Disease and Rifaximin: An Evidence-Based Review Antibiotics diverticulosis diverticular disease acute diverticulitis rifaximin fiber supplementation microbiota |
| title | Diverticular Disease and Rifaximin: An Evidence-Based Review |
| title_full | Diverticular Disease and Rifaximin: An Evidence-Based Review |
| title_fullStr | Diverticular Disease and Rifaximin: An Evidence-Based Review |
| title_full_unstemmed | Diverticular Disease and Rifaximin: An Evidence-Based Review |
| title_short | Diverticular Disease and Rifaximin: An Evidence-Based Review |
| title_sort | diverticular disease and rifaximin an evidence based review |
| topic | diverticulosis diverticular disease acute diverticulitis rifaximin fiber supplementation microbiota |
| url | https://www.mdpi.com/2079-6382/12/3/443 |
| work_keys_str_mv | AT annapiccin diverticulardiseaseandrifaximinanevidencebasedreview AT marcogulotta diverticulardiseaseandrifaximinanevidencebasedreview AT stefanodibella diverticulardiseaseandrifaximinanevidencebasedreview AT paolamartingano diverticulardiseaseandrifaximinanevidencebasedreview AT lorysaveriacroce diverticulardiseaseandrifaximinanevidencebasedreview AT maurogiuffre diverticulardiseaseandrifaximinanevidencebasedreview |